Molecular Insight Acquires Novartis’ Onalta
This article was originally published in The Pink Sheet Daily
Acquisition of the radiolabeled oncologic peptide is firm’s second deal in the past week.
You may also be interested in...
The Cambridge, Mass. biotech will develop the compound as a radiotherapeutic for malignant melanoma.
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.